CA
NZ
UK
AU
IND
US
Inhibikase Therapeutics (NASDAQ: IKT) announced a corporate update through a regulatory filing on July 14, 2026. The disclosure focused on capital-raising efforts via its at-the-market (ATM) offering mechanism. The filing adhered to requirements under the Securities Exchange Act of 1934.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) has detailed a refreshed approach to research and development, concentrating on its advanced programs and forthcoming pipeline candidates. The information was presented at a recent corporate briefing.
Wall Street analysts are recalibrating expectations for Alnylam Pharmaceuticals as the RNA interference therapeutics sector undergoes significant shifts. These adjustments reflect broader changes in the biotech environment, particularly for companies developing treatments for rare and progressive diseases like transthyretin amyloidosis (ATTR).
Medical device stocks gained momentum after AngioDynamics reported stronger-than-expected Q4 2026 earnings, signaling resilience in the healthcare sector. The results lifted investor sentiment toward companies specializing in vascular and minimally invasive technologies, with ripple effects across related equities.
Edwards Lifesciences Corp. (NYSE: EW) has been hit with a $10 million penalty for antitrust violations related to its $115 million acquisition of JC Medical. The Federal Trade Commission also fined JC Medical $2 million, marking the largest combined penalty ever for failing to …
Evotec SE’s decision to slash its 2026 financial outlook sent ripples through the contract research and biotech sectors, raising concerns about broader partnership execution risks among drug development service providers. The company’s warning of a potential annual loss underscores the fragility of revenue streams …
The combined entity will operate under the leadership of CEO Dr. Andrew Cheng and will prioritize the development of AVR-001, a long-acting cyclic peptide IL-23 receptor antagonist that Avere has licensed from Hansoh Pharma. The ownership structure of the deal reflects Avere's position as …
PMN310 is designed as a selective antibody targeting toxic amyloid-beta oligomers, a specific and increasingly scrutinized form of the amyloid-beta protein implicated in Alzheimer's disease pathology. Unlike some earlier-generation amyloid-targeting therapies that bind more broadly across various forms of amyloid-beta, including plaque deposits, PMN310's …
The royalty financing arrangement with Healthcare Royalty involves Spero monetizing future milestone payments and sales royalties tied to its approved oral antibiotic, Utebzi, which is currently licensed to GSK. This structure allows Spero to convert what would otherwise be a stream of future, uncertain …
The long-term extension data, drawn from 34 patients with up to 15.9 months of drug exposure, showed a 92% reduction in treated bleeding events, a substantial improvement that speaks to sutacimig's potential to meaningfully reduce the bleeding burden faced by patients with this rare …
Please wait processing your request...